The FDA on October 16, 2023, approved KEYTRUDA® with Platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent KEYTRUDA® as post-surgical adjuvant treatment for resectable (tumors 4 cm or more, or node positive) Non-Small Cell Lung Cancer (NSCLC). KEYTRUDA® is a product of Merck & Co., Inc.
Bottom Ad
Advertisement
Subscribe
